Some of the key companies in the Neuropathic Pain Market include Eli Lilly, Pfizer, Daichi Sankyo, WEX Pharmaceuticals, Lexicon Pharmaceuticals, and Bayer among others. In a market where generic antidepressants dominate the market, market access and reimbursement approval play a major role in the successful launch of novel expensive therapies.
DelveInsight’s “Neuropathic Pain Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Neuropathic Pain market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Neuropathic Pain drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Neuropathic Pain treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Neuropathic Pain: An Overview
According to the International Association for the Study of Pain (IASP), neuropathic pain is defined as “pain initiated or caused by a primary lesion or dysfunction in the nervous system. Chronic neuropathic pain is common and may be related to an underlying health condition such as cancer or diabetic neuropathy, or it could be related to treatments such as chemotherapy.
According to the International Classification of Diseases 11th Revision, 2018, chronic neuropathic pain is mainly classified into two: Chronic peripheral neuropathic pain and Chronic central neuropathic pain. The pain is usually described as a burning sensation, and affected areas are often sensitive to the touch. Symptoms of neuropathic pain may also include excruciating pain, pins, and needles, difficulty correctly sensing temperatures, and numbness. Some people may find it hard to wear thick clothes, as even slight pressure can aggravate the pain.
The primary goals of treatment for neuropathic pain are to manage the pain as much as possible and to minimize the negative side effects of the treatment. The International Association for the Study of Pain, proposed gabapentinoids, tricyclic antidepressants (TCAs), and selective serotonin–norepinephrine reuptake inhibitors (SNRI) as the first-line drugs for neuropathic pain. Lidocaine, Capsaicin, and Tramadol have been proposed as the second-line treatment, while strong opioids (Morphine and Oxycodone) and botulinum toxin-A (BTX-A) were included as third-line treatments for peripheral neuropathic pain.
Neuropathic Pain Market Key Facts
According to Bouhassira D , the prevalence of neuropathic pain in the general population may be as high as 7 to 8% accounting for 20 to 25% of individuals with chronic pain.
As per Liedgens H et al. (2016), neuropathic pain is estimated to affect 7%–8% of the population in Europe, yet some estimates have suggested that as many as 20% of adults in Europe may be affected and that close to half of those are affected on a daily basis.
According to a study by Mbrah A K et al. (2022), the prevalence of neuropathic pain was 14.6%. Among those with neuropathic pain, 19.7% had diabetic neuropathy, 27.3% had back and neck pain with neuropathic involvement, and 25.1% had hereditary or idiopathic neuropathy in the US population.
According to et al.a study by Yawn et al., in 2009, the prevalence of chronic neuropathic pain (NeP) was 12% in the US. As per a study by Torrance et al. (2006) prevalence of chronic NeP was 11.4% in the UK.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Neuropathic Pain pipeline therapies. It also thoroughly assesses the Neuropathic Pain market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Neuropathic Pain drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Neuropathic Pain Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Neuropathic Pain epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Neuropathic Pain epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Neuropathic Pain Epidemiology, Segmented as –
Gender-specific Diagnosed Prevalent Cases of Neuropathic Pain (NP) in the 7MM [2019–2032]
Total Prevalent Cases of Neuropathic Pain (NP) in the 7MM [2019–2032]
Diagnosed Prevalent Cases of Neuropathic Pain (NP) in the 7MM [2019–2032]
Type-specific Diagnosed Prevalent Cases of Neuropathic Pain (NP) in the 7MM [2019–2032]
Neuropathic Pain Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Neuropathic Pain market or expected to be launched during the study period. The analysis covers the Neuropathic Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Neuropathic Pain drugs based on their sale and market share.
The report also covers the Neuropathic Pain pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Neuropathic Pain companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Neuropathic Pain Market Will Evolve and Grow by 2032 @
Neuropathic Pain Therapeutics Analysis
The contemporary treatment objectives for neuropathic pain encompass a comprehensive approach that aims to alleviate discomfort, improve patients’ quality of life, and address the underlying causes of pain. The present treatment objective for neuropathic pain involves a patient-centered approach that prioritizes effective pain relief, restoration of functional abilities, enhancement of overall quality of life, and the mitigation of treatment-related side effects.
The Special Interest Group on Neuropathic Pain (NeuPSIG) proposed gabapentinoids, tricyclic antidepressants (TCAs), and selective serotonin–norepinephrine reuptake inhibitors (SNRI) as the first-line drugs for neuropathic pain. Lidocaine, Capsaicin, and Tramadol have been proposed as the second-line treatment, while strong opioids (Morphine and Oxycodone) and botulinum toxin-A (BTX-A) were included as third-line treatments for peripheral neuropathic pain. Spinal Cord Stimulation (SCS) constitutes an alternative therapy useful for patients who are not responsive to standard treatment.
Neuropathic Pain Companies Actively Working in the Therapeutics Market Include
And Many Others
Emerging and Marketed Neuropathic Pain Therapies Covered in the Report Include:
Halneuron – WEX Pharmaceuticals Inc
LX9211 – Lexicon Pharmaceuticals Inc
BAY2395840 – Bayer
Senza Omnia: Nevro
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Neuropathic Pain Competitive Intelligence Analysis
4. Neuropathic Pain Market Overview at a Glance
5. Neuropathic Pain Disease Background and Overview
6. Neuropathic Pain Patient Journey
7. Neuropathic Pain Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Neuropathic Pain Treatment Algorithm, Current Treatment, and Medical Practices
9. Neuropathic Pain Unmet Needs
10. Key Endpoints of Neuropathic Pain Treatment
11. Neuropathic Pain Marketed Therapies
12. Neuropathic Pain Emerging Drugs and Latest Therapeutic Advances
13. Neuropathic Pain Seven Major Market Analysis
14. Attribute Analysis
15. Neuropathic Pain Market Outlook (In US, EU5, and Japan)
16. Neuropathic Pain Companies Active in the Market
17. Neuropathic Pain Access and Reimbursement Overview
18. KOL Views on the Neuropathic Pain Market
19. Neuropathic Pain Market Drivers
20. Neuropathic Pain Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Cardiac Monitoring System Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Cardiac Monitoring System market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. Moreover, it covers the key companies, emerging products, and commercial & regulatory development, in the Cardiac Monitoring System Market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States